{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T09:12:29Z","timestamp":1778231549441,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BJC Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>800\u2009mg avelumab, given every 2 weeks, in combination with axitinib, is an approved first-line treatment option for patients with metastatic renal cell carcinoma (mRCC). Less frequent administration of avelumab would be preferable to patients and service providers but has not been previously explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analysed the clinical outcomes of patients from two academic centres who received 4-weekly avelumab plus axitinib between Oct 2019 and Oct 2023. Patients in cohort 1 (C1) were treated with 4-weekly avelumab from the start of therapy. Patients in cohort 2 (C2) initially received standard 2-weekly avelumab and were later switched to 4-weekly infusions. Overall response rate (ORR), progression-free survival (PFS), overall survival (OS) and toxicities leading to dose reductions or cessation were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 94 patients in total, 46 patients in C1 and 48 patients in C2. The majority (56%) of patients in both cohorts had IMDC favourable-risk disease. The ORR in C1 was 53% and the median PFS was 22.1 months. In C2, the median time to switch was 4.9 months (range 1.8\u201335.6) and median time on 4-weekly avelumab was 16.7 months (range 0.9\u201339.1). Toxicity was consistent with prior reports. Limitations include retrospective design.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These preliminary data support prospective evaluation of modified avelumab scheduling in patients with mRCC. Reducing treatment burden stands to improve patient quality of life and lower associated costs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s44276-026-00224-y","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:56:15Z","timestamp":1778230575000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["4-weekly avelumab plus axitinib in patients with metastatic renal cell carcinoma"],"prefix":"10.1038","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8470-7481","authenticated-orcid":false,"given":"Naveen S.","family":"Vasudev","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umair","family":"Aleem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Humphries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manon","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Pickwell-Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christy","family":"Ralph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satinder","family":"Jagdev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Dearden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Waddell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"224_CR1","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","volume":"35","author":"T Powles","year":"2024","unstructured":"Powles T, Albiges L, Bex A, Comperat E, Grunwald V, Kanesvaran R, et al. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35:692\u2013706.","journal-title":"Ann Oncol"},{"key":"224_CR2","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1103\u201315.","journal-title":"N Engl J Med"},{"key":"224_CR3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.annonc.2024.12.008","volume":"36","author":"TK Choueiri","year":"2025","unstructured":"Choueiri TK, Penkov K, Uemura H, Campbell MT, Pal S, Kollmannsberger C, et al. Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial. Ann Oncol. 2025;36:387\u201392.","journal-title":"Ann Oncol"},{"key":"224_CR4","first-page":"1","volume":"5","author":"A Renner","year":"2019","unstructured":"Renner A, Burotto M, Rojas C. Immune checkpoint inhibitor dosing: can we go lower without compromising clinical efficacy? J Glob Oncol. 2019;5:1\u20135.","journal-title":"J Glob Oncol"},{"key":"224_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.906251","volume":"12","author":"M Jiang","year":"2022","unstructured":"Jiang M, Hu Y, Lin G, Chen C. Dosing regimens of immune checkpoint inhibitors: attempts at lower dose, less frequency, shorter course. Front Oncol. 2022;12:906251.","journal-title":"Front Oncol"},{"key":"224_CR6","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41416-019-0570-y","volume":"121","author":"S Danson","year":"2019","unstructured":"Danson S, Hook J, Marshall H, Smith A, Bell S, Rodwell S, et al. Are we over-treating with checkpoint inhibitors? Br J Cancer. 2019;121:629\u201330.","journal-title":"Br J Cancer"},{"key":"224_CR7","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1200\/JCO.23.00236","volume":"42","author":"NS Vasudev","year":"2024","unstructured":"Vasudev NS, Ainsworth G, Brown S, Pickering L, Waddell T, Fife K, et al. Standard versus modified ipilimumab, in combination with nivolumab, in advanced renal cell carcinoma: a randomized phase II trial (PRISM). J Clin Oncol. 2024;42:312\u201323.","journal-title":"J Clin Oncol"},{"key":"224_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2022.107030","volume":"124","author":"S Merrick","year":"2023","unstructured":"Merrick S, Nankivell M, Quartagno M, Clarke CS, Joharatnam-Hogan N, Waddell T, et al. REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): a multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers. Contemp Clin Trials. 2023;124:107030.","journal-title":"Contemp Clin Trials"},{"key":"224_CR9","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1200\/JCO.22.01015","volume":"41","author":"VM Patil","year":"2023","unstructured":"Patil VM, Noronha V, Menon N, Rai R, Bhattacharjee A, Singh A, et al. Low-dose immunotherapy in head and neck cancer: a randomized study. J Clin Oncol. 2023;41:222\u201332.","journal-title":"J Clin Oncol"},{"key":"224_CR10","doi-asserted-by":"publisher","first-page":"e219","DOI":"10.1016\/S1470-2045(23)00095-5","volume":"24","author":"E Ghorani","year":"2023","unstructured":"Ghorani E, Quartagno M, Blackhall F, Gilbert DC, O\u2019Brien M, Ottensmeier C, et al. REFINE-lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment. Lancet Oncol. 2023;24:e219\u2013e27.","journal-title":"Lancet Oncol"},{"key":"224_CR11","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1200\/JCO.2024.42.4_suppl.386","volume":"42","author":"PD Nathan","year":"2024","unstructured":"Nathan PD, Charnley N, Frazer R, McGrane J, Muazzam I, Pillai M, et al. A UK real-world observational study of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): outcomes at 36 months post treatment initiation. J Clin Oncol. 2024;42:386.","journal-title":"J Clin Oncol"},{"key":"224_CR12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/iju.15345","volume":"31","author":"T Kato","year":"2024","unstructured":"Kato T, Nakano Y, Hongo F, Katano H, Miyagawa T, Ueda K, et al. Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: a multicenter, retrospective, observational study (J-DART). Int J Urol. 2024;31:265\u201372.","journal-title":"Int J Urol"},{"key":"224_CR13","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1200\/JCO.2025.43.5_suppl.474","volume":"43","author":"AS Merseburger","year":"2025","unstructured":"Merseburger AS, Baklanova O, Garlonta VT, Androulakis NE, Christopoulou A, Timotheadou E, et al. Real-world effectiveness and safety of first-line (1L) avelumab + axitinib in patients with advanced renal cell carcinoma (aRCC): primary analysis of the AVION study. J Clin Oncol. 2025;43:474.","journal-title":"J Clin Oncol"},{"key":"224_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/curroncol32010011","volume":"32","author":"I Tsimafeyeu","year":"2024","unstructured":"Tsimafeyeu I, Chubenko V, Baklanova O, Kalpinskiy A, Safina S, Lebedinets A, et al. Real-world efficacy and safety of avelumab plus axitinib in metastatic renal cell carcinoma: results from the ambispective RAVE-renal study. Curr Oncol. 2024;32:11.","journal-title":"Curr Oncol"},{"key":"224_CR15","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S1470-2045(17)30239-5","volume":"18","author":"CR Heery","year":"2017","unstructured":"Heery CR, O\u2019Sullivan-Coyne G, Madan RA, Cordes L, Rajan A, Rauckhorst M, et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol. 2017;18:587\u201398.","journal-title":"Lancet Oncol"},{"key":"224_CR16","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167\u201375.","journal-title":"J Clin Oncol"},{"key":"224_CR17","doi-asserted-by":"publisher","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","volume":"21","author":"A Patnaik","year":"2015","unstructured":"Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res. 2015;21:4286\u201393.","journal-title":"Clin Cancer Res"},{"key":"224_CR18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563\u20137.","journal-title":"Nature"},{"key":"224_CR19","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1182\/blood-2024-201172","volume":"144","author":"A Korula","year":"2024","unstructured":"Korula A, Arunachalam A, Kulkarni U, Venkateswara Rao Datari P, Mathew S, Anand A, et al. Rationalization of anti-PD-1 therapy using receptor occupancy data to guide drug dosing - a single arm phase II trial using immunomodulation in relapsed\/refractory Hodgkin lymphoma. Blood. 2024;144:647.","journal-title":"Blood"},{"key":"224_CR20","unstructured":"National Institiute for Health and Care Excellence. Avelumab with axitinib for untreated advanced renal cell carcinoma. National Institiute for Health and Care Excellence; 2020."},{"key":"224_CR21","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/s41416-023-02367-y","volume":"129","author":"A Wesevich","year":"2023","unstructured":"Wesevich A, Goldstein DA, Paydary K, Peer CJ, Figg WD, Ratain MJ. Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies. Br J Cancer. 2023;129:1389\u201396.","journal-title":"Br J Cancer"}],"container-title":["BJC Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44276-026-00224-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-026-00224-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-026-00224-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:56:19Z","timestamp":1778230579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44276-026-00224-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["224"],"URL":"https:\/\/doi.org\/10.1038\/s44276-026-00224-y","relation":{},"ISSN":["2731-9377"],"issn-type":[{"value":"2731-9377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NV, who is an Associate Editor for this journal, has received speaker\/advisory fees from Merck, Ipsen, Johnson & Johnson, Eisai, Recordati and MSD. TW has received speaker\/advisory fees from Merck, Eisai, MSD, Ipsen, Pfizer, BMS and Recordati. HD has received speaker\/advisory fees from Merck, Astellas, AstraZeneca, Ipsen, Johnson & Johnson, Eisai and Bayer. All other authors have no competing interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This was a retrospective study conducted in accordance with the Declaration of Helsinki. This research complied with all relevant ethical guidelines. Since the manuscript contains no identifiable patient information, patient consent was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The data published in this manuscript contain no identifiable patient information or individual details. No informed consent was needed per institutional review board because this is a retrospective analysis without any patient identifiers.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"23"}}